



5<sup>th</sup> April 2016

Announcements

National Stock Exchange of Australia

PO Box 283

NEWCASTLE NSW 2300

**Market Announcement – iQX Acquires Interest in Novel and First in Class Biologic Compound Originated at McGill University**

**iQX Limited (NSX:IQX)** is pleased to announce that it has acquired an interest in a consortium that owns and is commercialising a novel and first in class biologic compound, accompanying biomarker and genetic stem cell development program. The research program and the resulting intellectual property originated from McGill University in Canada. The current clinical development strategy has a global focus, however, it is anticipated that Australia will play a major role in the clinical development of this novel antineoplastic compound.

Currently the compound will be exiting the preclinical phase and in the next few months we intend to file with the US regulatory agency an Investigative New Drug Application that will enable us to commence Phase I clinical trials.

This novel biologic compound and its Biomarker are being developed for multiple oncology indications. Primarily the development plan is focused on breast cancer, melanoma and prostate cancer.

Further information will be released to the market in due course as the program progresses.



Kelvin Boateng  
Company Secretary  
iQX Limited

**For further information, please contact our Corporate Advisors below:**

**Investors**

iQ3Corp Investor Relations Team

Email: [investor.relations@iq3corp.com](mailto:investor.relations@iq3corp.com)

Phone: +61 2 8239 5400

**About iQX Limited**

*iQX Ltd is a specialist life science investment organization*

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400

New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630

London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

**Disclaimer**

Subject to any continuing disclosure obligations under the laws of the Commonwealth of Australia or the NSX listing rules, iQX Ltd (iQX or the Company) disclaims any perceived intent or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. Expressions such as 'believe', 'expect', 'anticipate', 'indicate', 'contemplate', 'target', 'plan', 'intends', 'continue', 'budget', 'estimate', 'may', 'will', 'schedule' and similar expressions identify forward-looking statements.

The following cautionary statements qualify all forward-looking statements made in this announcement. In particular, the direction and strategies adopted by iQX and detailed in this announcement represents the Company's strategic planning and decision-making practices and are based on current expectations. iQX's business is subject to uncertainties, risks and contingencies, many of which are outside the control of, and are presently unknown to the Company, and could cause the actual conduct, results, performance or achievements of iQX to vary in a material way from those expressed or implied in this announcement. Investors are cautioned that forward-looking statements are not guarantees of future performance or outcomes, and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Additional information concerning iQX's business, its associated risks and operations can be found in its periodic announcements to NSX.